Purple Biotech (PPBT) Cash from Financing Activities (2017 - 2026)
Purple Biotech's (PPBT) quarterly Cash from Financing Activities came in at -$64000.0 in Q1 2026, down 162.14% year-on-year from $103000.0 in Q1 2025, and down 121.55% on a QoQ basis from $297000.0 in Q4 2025.
Purple Biotech (PPBT) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 10 years of Cash from Financing Activities data on file, last reported at -$64000.0 in Q1 2026.
- On a quarterly basis, Cash from Financing Activities fell 162.14% year-over-year to -$64000.0 in Q1 2026; TTM through Mar 2026 was $6.2 million, a 6.7% decrease from a year earlier, with the FY2025 full-year figure at $6.3 million, down 6.51% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$64000.0, down from $297000.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for PPBT reached as high as $5.6 million in Q3 2025 and fell as low as -$64000.0 in Q1 2026.
- Historically, Cash from Financing Activities has averaged $1.2 million across 5 years, with a median of $366000.0 in 2025.
- Across the five-year window, Cash from Financing Activities surged 4670.79% in 2023 and tumbled 162.14% in 2026, its largest moves.
- Year by year, Cash from Financing Activities stood at $89000.0 in 2022, then jumped by 4670.79% to $4.2 million in 2023, then fell by 7.23% to $3.9 million in 2024, then tumbled by 92.46% to $297000.0 in 2025, then tumbled by 121.55% to -$64000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were -$64000.0 in Q1 2026, $297000.0 in Q4 2025, and $5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Purple Biotech | 1.33 Bn | 1.33 Bn | - | -64,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -64,000.00 |
| Mar 31, 2026 | -64,000.00 |
| Dec 31, 2025 | 297,000.00 |
| Dec 31, 2025 | 297,000.00 |
| Sep 30, 2025 | 5.57 Mn |
| Sep 30, 2025 | 5.57 Mn |
| Jun 30, 2025 | 366,000.00 |
| Jun 30, 2025 | 366,000.00 |
| Mar 31, 2025 | 103,000.00 |
| Mar 31, 2025 | 103,000.00 |
| Dec 31, 2024 | 3.94 Mn |
| Dec 31, 2024 | 3.94 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 433,000.00 |
| Jun 30, 2024 | 433,000.00 |
| Mar 31, 2024 | 268,000.00 |
| Mar 31, 2024 | 268,000.00 |
| Dec 31, 2023 | 4.25 Mn |
| Dec 31, 2023 | 4.25 Mn |